Applying the AIM Concept in Support of Developing Improved In Vitro–In Vivo Relationships for OIPs - Good Cascade Impactor Practices, AIM and EDA for Orally Inhaled Products - page 368

100

Alveolor/Interstitium
Extrathoracic
Bronchial

80

60

Bronchiolar

40

20

0

0 5 10 15

Aerodynamic Diameter ( m)

μ

Fig. 12.1 Comparison between defi nitions for size-segregated pollutant aerosol (PM-series),
ICRP lung deposition subfractions for a healthy male (PIFR = 28.3 L/min; V = 2 L), and cut-point
sizes for the eight-stage nonviable ACI at 28.3 L/min

Fig. 12.2 Schematic of USP/
Ph.Eur. induction port inlet

geometry on aerosol transport processes, the compendial inlet has the same
internal dimensions regardless of the end user of the product (infant, small child, or
adult). There is also a signifi cant body of evidence identifying the divergence
between lung deposition data and in vitro measurements of metrics derived from
OIP APSDs by full-resolution systems equipped with the USP/Ph.Eur. induction
port [ 10 - 12 ].